AAIPharma's Formulation Development group has improved the pharmacokinetics of several drugs by developing technologies, processes, expertise, and intellectual property intended to improve a products efficacy, safety, and patient compliance. AAIPharma's development program has earned a reputation for solving complex drug delivery challenges for its clients and partners. With a number of drug delivery platforms, AAIPharma can be a key resource for new tools and strategies to expand the usefulness of your medicines in effective patient care. Our portfolio of drug delivery technologies provides vehicles to deliver the active pharmaceutical ingredient in ways that are more effective, more efficient, or provide other properties that better meet the therapeutic needs of the patient base. These value-added enhancements that improve the therapeutic performance and market position of your drug product feature:
ProSorb Tablet, soft, or hard gelatin capsule dosage forms for improved oral drug delivery.
Solubilized formulations
Faster onset of activity
Higher peak blood levels
Greater AUC
Lower COGS
ProLiquitab Novel technology allows solubilized drug to be delivered as a tablet.
Solid dosage form manufacturing with liquid matrix benefits
Improves bioavailability of poorly soluble drugs in tablet form
Scalable process using conventional tablet manufacturing equipment
ProLonic Combines the benefits of erosion and pH dependent drug release to target the lower gastrointestinal tract
Selectable time of onset of drug delivery.
Prolonged delivery
Flexibility to allow pulsatile delivery
Multiple drug release capability
ProLipid Microemulsion based tablet or hard gelatin capsule for poorly bioavailable drugs
Improved bioavailability.
Less API required for development
Liquid matrix enables containment of highly potent drugs. We are constantly adding to our portfolio of drug delivery options and can even customize a program to develop a delivery option specifically tailored to meet your needs.
